skip to main content
Idioma:
Resultados 1 2 3 next page
Refinado por: tipo de recurso: Artigos remover The Lancet remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Cope, Andrew P ; Jasenecova, Marianna ; Vasconcelos, Joana C ; Filer, Andrew ; Raza, Karim ; Qureshi, Sumera ; D'Agostino, Maria Antonietta ; McInnes, Iain B ; Isaacs, John D ; Pratt, Arthur G ; Fisher, Benjamin A ; Buckley, Christopher D ; Emery, Paul ; Ho, Pauline ; Buch, Maya H ; Ciurtin, Coziana ; van Schaardenburg, Dirkjan ; Huizinga, Thomas ; Toes, René ; Georgiou, Evangelos ; Kelly, Joanna ; Murphy, Caroline ; Prevost, A Toby ; Norton, Sam ; Lempp, Heidi ; Opena, Maria ; Subesinghe, Sujith ; Garrood, Toby ; Menon, Bina ; Ng, Nora ; Douglas, Karen ; Koutsianas, Christos ; Cooles, Faye ; Falahee, Marie ; Echavez-Naguicnic, Irene ; Bharadwaj, Anurag ; Villaruel, Michael ; Pande, Ira ; Collins, David ; Pegler, Suzannah ; Raizada, Sabrina ; Siebert, Stefan ; Fragoulis, George ; Guinto, Jesusa ; Galloway, James ; Rutherford, Andrew ; Barnes, Theresa ; Jeffrey, Helen ; Patel, Yusuf ; Batley, Michael ; O'Reilly, Brendan ; Venkatachalam, Srivinisan ; Sheeran, Thomas ; Gorman, Claire ; Reynolds, Piero ; Khan, Asad ; Gullick, Nicola ; Banerjee, Siwalik ; Mankia, Kulveer ; Jordan, Deepak ; Rowlands, Jane ; Starmans-Kool, Mirian ; Taylor, James ; Nandi, Pradip ; Sahbudin, Ilfita ; Maybury, Mark ; Hider, Samantha ; Barcroft, Ann ; McNally, Jeremy ; Kitchen, Jo ; Nisar, Muhammad ; Quick, Vanessa

The Lancet (British edition), 2024-03, Vol.403 (10429), p.838-849 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Questions about the BE OPTIMAL trial – Authors' reply
Questions about the BE OPTIMAL trial – Authors' reply
Material Type:
Artigo 		Adicionar ao Meu Espaço

Questions about the BE OPTIMAL trial – Authors' reply

McInnes, Iain B ; Merola, Joseph F

The Lancet (British edition), 2023-06, Vol.401 (10392), p.1928-1928 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Questions about the BE COMPLETE trial – Authors' reply
Questions about the BE COMPLETE trial – Authors' reply
Material Type:
Artigo 		Adicionar ao Meu Espaço

Questions about the BE COMPLETE trial – Authors' reply

Merola, Joseph F ; McInnes, Iain B

The Lancet (British edition), 2023-06, Vol.401 (10392), p.1927-1927 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK
Material Type:
Artigo 		Adicionar ao Meu Espaço

Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK

Conrad, Nathalie ; Misra, Shivani ; Verbakel, Jan Y ; Verbeke, Geert ; Molenberghs, Geert ; Taylor, Peter N ; Mason, Justin ; Sattar, Naveed ; McMurray, John J V ; McInnes, Iain B ; Khunti, Kamlesh ; Cambridge, Geraldine

The Lancet (British edition), 2023-06, Vol.401 (10391), p.1878-1890 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Merola, Joseph F ; Landewé, Robert ; McInnes, Iain B ; Mease, Philip J ; Ritchlin, Christopher T ; Tanaka, Yoshiya ; Asahina, Akihiko ; Behrens, Frank ; Gladman, Dafna D ; Gossec, Laure ; Gottlieb, Alice B ; Thaçi, Diamant ; Warren, Richard B ; Ink, Barbara ; Assudani, Deepak ; Bajracharya, Rajan ; Shende, Vishvesh ; Coarse, Jason ; Coates, Laura C

The Lancet (British edition), 2023-01, Vol.401 (10370), p.38-48 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

McInnes, Iain B ; Asahina, Akihiko ; Coates, Laura C ; Landewé, Robert ; Merola, Joseph F ; Ritchlin, Christopher T ; Tanaka, Yoshiya ; Gossec, Laure ; Gottlieb, Alice B ; Warren, Richard B ; Ink, Barbara ; Assudani, Deepak ; Bajracharya, Rajan ; Shende, Vishvesh ; Coarse, Jason ; Mease, Philip J

The Lancet (British edition), 2023-01, Vol.401 (10370), p.25-37 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

McInnes, Iain B ; Behrens, Frank ; Mease, Philip J ; Kavanaugh, Arthur ; Ritchlin, Christopher ; Nash, Peter ; Masmitja, Jordi Gratacós ; Goupille, Philippe ; Korotaeva, Tatiana ; Gottlieb, Alice B ; Martin, Ruvie ; Ding, Kevin ; Pellet, Pascale ; Mpofu, Shephard ; Pricop, Luminita

The Lancet (British edition), 2020-05, Vol.395 (10235), p.1496-1505 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Mease, Philip J ; Rahman, Proton ; Gottlieb, Alice B ; Kollmeier, Alexa P ; Hsia, Elizabeth C ; Xu, Xie L ; Sheng, Shihong ; Agarwal, Prasheen ; Zhou, Bei ; Zhuang, Yanli ; van der Heijde, Désirée ; McInnes, Iain B

The Lancet (British edition), 2020-04, Vol.395 (10230), p.1126-1136 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Ritchlin, Christopher T ; Kavanaugh, Arthur ; Merola, Joseph F ; Schett, Georg ; Scher, Jose U ; Warren, Richard B ; Gottlieb, Alice B ; Assudani, Deepak ; Bedford-Rice, Kathy ; Coarse, Jason ; Ink, Barbara ; McInnes, Iain B

The Lancet (British edition), 2020-02, Vol.395 (10222), p.427-440 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
The extending scope of kinase inhibition in immune diseases
The extending scope of kinase inhibition in immune diseases
Material Type:
Artigo 		Adicionar ao Meu Espaço

The extending scope of kinase inhibition in immune diseases

McInnes, Iain B ; Siebert, Stefan

The Lancet (British edition), 2018-12, Vol.392 (10162), p.2328-2331 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.